Universal Beteiligungs und Servicegesellschaft mbH Makes New $18.08 Million Investment in Moderna, Inc. (NASDAQ:MRNA)

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 434,914 shares of the company's stock, valued at approximately $18,084,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.11% of Moderna at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Allworth Financial LP increased its position in Moderna by 17.3% in the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company's stock worth $73,000 after purchasing an additional 281 shares during the last quarter. Howard Capital Management Inc. increased its holdings in shares of Moderna by 3.1% during the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock valued at $416,000 after acquiring an additional 297 shares during the last quarter. Itau Unibanco Holding S.A. increased its holdings in shares of Moderna by 51.2% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after acquiring an additional 343 shares during the last quarter. Commonwealth Equity Services LLC increased its holdings in shares of Moderna by 0.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock valued at $3,099,000 after acquiring an additional 345 shares during the last quarter. Finally, Larson Financial Group LLC increased its holdings in shares of Moderna by 39.1% during the 4th quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock valued at $53,000 after acquiring an additional 356 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Up 2.8%

Shares of MRNA stock traded up $0.76 during mid-day trading on Tuesday, reaching $27.81. The stock had a trading volume of 13,422,532 shares, compared to its average volume of 8,220,742. The firm's 50 day simple moving average is $26.23 and its 200 day simple moving average is $33.71. Moderna, Inc. has a one year low of $23.15 and a one year high of $158.82. The firm has a market cap of $10.76 billion, a PE ratio of -3.00 and a beta of 1.86.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The company had revenue of $108.00 million during the quarter, compared to the consensus estimate of $130.35 million. During the same quarter last year, the company earned ($3.07) EPS. The company's quarterly revenue was down 35.3% on a year-over-year basis. Sell-side analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of analyst reports. Bank of America lowered their price objective on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a report on Tuesday, February 11th. Royal Bank of Canada lowered their price objective on Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. Citigroup initiated coverage on Moderna in a report on Thursday, March 13th. They set a "neutral" rating and a $40.00 price objective on the stock. JPMorgan Chase & Co. lowered their price objective on Moderna from $33.00 to $26.00 and set an "underweight" rating on the stock in a report on Thursday, May 22nd. Finally, William Blair restated a "market perform" rating on shares of Moderna in a research note on Monday. Four investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $53.58.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.